Iran intends to produce 40 million Sputnik V doses per year
Iranian government spokesman Ali Rabei said Tehran plans to increase the local production of the Russian Sputnik V vaccine to 40 million doses per year. It will be possible after the joint pharmaceutical company of Iran and Russia starts working.
Recently, Iran and Russia have reached an agreement to establish joint production of Russia's Sputnik V COVID-19 vaccine. Rabei said the operation of the enterprise is expected to start within a month.
At the same time, the Gamaleya Center, which developed Sputnik V, will participate in the joint venture. "It is expected that the production capacity will exceed 40 million doses of the vaccine," RIA Novosti cited him as saying.